CN107613981A - 布罗莫结构域抑制剂 - Google Patents

布罗莫结构域抑制剂 Download PDF

Info

Publication number
CN107613981A
CN107613981A CN201680032770.1A CN201680032770A CN107613981A CN 107613981 A CN107613981 A CN 107613981A CN 201680032770 A CN201680032770 A CN 201680032770A CN 107613981 A CN107613981 A CN 107613981A
Authority
CN
China
Prior art keywords
pharmaceutical composition
cyclopropylmethoxy
methylsulfonylphenyl
methylisoquinolin
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680032770.1A
Other languages
English (en)
Chinese (zh)
Inventor
胡安·曼纽尔·贝坦科特
杰弗里·艾伦·斯塔福德
赖安·斯坦斯菲尔德
詹姆斯·马文·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Quanticel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quanticel Pharmaceuticals Inc filed Critical Quanticel Pharmaceuticals Inc
Publication of CN107613981A publication Critical patent/CN107613981A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201680032770.1A 2015-04-22 2016-04-22 布罗莫结构域抑制剂 Pending CN107613981A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562151205P 2015-04-22 2015-04-22
US62/151,205 2015-04-22
PCT/US2016/029029 WO2016172618A1 (en) 2015-04-22 2016-04-22 Bromodomain inhibitor

Publications (1)

Publication Number Publication Date
CN107613981A true CN107613981A (zh) 2018-01-19

Family

ID=57143581

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032770.1A Pending CN107613981A (zh) 2015-04-22 2016-04-22 布罗莫结构域抑制剂

Country Status (22)

Country Link
US (1) US20160310423A1 (enExample)
EP (1) EP3285770A4 (enExample)
JP (1) JP2018513863A (enExample)
KR (1) KR20170139119A (enExample)
CN (1) CN107613981A (enExample)
AR (1) AR104340A1 (enExample)
AU (1) AU2016252992A1 (enExample)
BR (1) BR112017022691A2 (enExample)
CA (1) CA2983446C (enExample)
CL (1) CL2017002679A1 (enExample)
CO (1) CO2017011482A2 (enExample)
EA (1) EA201792317A1 (enExample)
EC (1) ECSP17071545A (enExample)
HK (1) HK1243948A1 (enExample)
IL (1) IL255120B (enExample)
MX (2) MX390077B (enExample)
PE (1) PE20180036A1 (enExample)
PH (1) PH12017501933A1 (enExample)
SG (1) SG11201708627TA (enExample)
TW (1) TW201642860A (enExample)
WO (1) WO2016172618A1 (enExample)
ZA (1) ZA201707186B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823152A (zh) * 2018-07-23 2021-05-18 赛尔基因昆蒂赛尔研究公司 用于制备布罗莫结构域抑制剂的方法

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
US10702517B2 (en) 2015-04-22 2020-07-07 Celgene Quanticel Research, Inc. Bromodomain inhibitor
GB201506872D0 (en) 2015-04-22 2015-06-03 Ge Oil & Gas Uk Ltd Novel compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂
ES2907840T3 (es) 2016-10-27 2022-04-26 Celgene Quanticel Res Inc Terapia combinada de inhibidor de proteína de bromodominio y extraterminal
US20220265618A1 (en) * 2021-02-22 2022-08-25 Celgene Quanticel Research, Inc. Methods of treating prostate cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136435A (zh) * 2011-12-30 2014-11-05 艾伯维公司 溴结构域抑制剂
US20150111885A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals Bromodomain inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420722D0 (en) * 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
GB0919434D0 (en) * 2009-11-05 2009-12-23 Glaxosmithkline Llc Novel compounds
CN110099685A (zh) * 2016-10-20 2019-08-06 赛尔基因光迪斯研究公司 溴结构域抑制剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104136435A (zh) * 2011-12-30 2014-11-05 艾伯维公司 溴结构域抑制剂
US20150111885A1 (en) * 2013-10-18 2015-04-23 Quanticel Pharmaceuticals Bromodomain inhibitors
CN105828820A (zh) * 2013-10-18 2016-08-03 赛尔基因昆蒂赛尔研究公司 布罗莫结构域抑制剂

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112823152A (zh) * 2018-07-23 2021-05-18 赛尔基因昆蒂赛尔研究公司 用于制备布罗莫结构域抑制剂的方法

Also Published As

Publication number Publication date
MX377159B (es) 2025-03-07
AU2016252992A1 (en) 2017-11-09
NZ736630A (en) 2024-03-22
EP3285770A1 (en) 2018-02-28
MX390077B (es) 2025-03-20
KR20170139119A (ko) 2017-12-18
WO2016172618A1 (en) 2016-10-27
JP2018513863A (ja) 2018-05-31
IL255120B (en) 2021-03-25
CL2017002679A1 (es) 2018-05-25
CA2983446C (en) 2024-04-09
MX2020010899A (es) 2022-02-15
BR112017022691A2 (pt) 2018-07-17
PE20180036A1 (es) 2018-01-09
US20160310423A1 (en) 2016-10-27
ECSP17071545A (es) 2017-12-01
AR104340A1 (es) 2017-07-12
EP3285770A4 (en) 2018-10-31
SG11201708627TA (en) 2017-11-29
CO2017011482A2 (es) 2018-01-31
IL255120A0 (en) 2017-12-31
CA2983446A1 (en) 2016-10-27
TW201642860A (zh) 2016-12-16
HK1243948A1 (zh) 2018-07-27
EA201792317A1 (ru) 2018-03-30
MX2017013501A (es) 2018-02-09
ZA201707186B (en) 2019-01-30
PH12017501933A1 (en) 2018-03-19

Similar Documents

Publication Publication Date Title
CN107613981A (zh) 布罗莫结构域抑制剂
CN105037355B (zh) Wnt信号传导途径的吲唑抑制剂及其治疗用途
JP2024056905A (ja) ブロモドメイン阻害剤
TWI828817B (zh) 用於治療或預防痛風或高尿酸血症之化合物晶型
CA3140412A1 (en) Compound for treating gout or hyperuricemia
JP2022510303A (ja) 痛風または高尿酸血症を処置または予防するための方法
US20230301983A1 (en) Bromodomain inhibitor
WO2023098872A1 (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
CN106963766B (zh) 一种氮杂螺酮类药物组合物及其制备方法
CN101830911B (zh) 一类噻吩并吡啶衍生物、其制备方法和用途
EP1844775B1 (en) Therapeutic agent for the treatment of herpes progenitalis after development of lesions
CA3121913C (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
JP2020532522A (ja) 感覚有毛細胞死を予防または処置するための化合物の結晶形態
CN106916168B (zh) 一种治疗重症胰腺炎的化合物及其制备方法
HK40056574A (en) Crystalline forms of a compound for treating or preventing gout or hyperuricemia
HK40056574B (zh) 用於治疗或预防痛风或高尿酸血症的化合物的晶型

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180119